| AdventHealth Research Institute

NCT05739383

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)

This study is currently enrolling.

Study CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter taken in ...

NCT06079190

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease

This study is currently enrolling.

We are conducting this research study to find out if study drug GSK4527226 [AL101], a drug being developed by GSK together with another company called Alector, can reduce the loss of memory and decline in daily functioning usua ...

NCT06305767

A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection

This study is currently enrolling.

To compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to DFS. Hypothesis (H1): V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS as assessed by the investigator ...

NCT05685004

Randomized controlled Phase 2b clinical trial to evaluate the safety and efficacy of TVI-Brain-1 combined with conformal radiotherapy and temozolomide compared to standard therapy as a treatment for newly diagnosed O6-methylguanine methyltransferase negative (MGMT unmethylated) grade 4 astrocytoma (glioblastoma multiforme; glioblastoma; GBM).

This study is currently enrolling.

This clinical trial is being performed because there is a need for safer and more effective treatments for glioblastomas. The purpose of this specific clinical study is to determine how safe and effective TVI-Brain-1 would be a ...

NCT05399654

INCLINE-101: A Phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors

This study is currently enrolling.

The purpose of this study is to test the safety of an investigational (experimental) drug, TAC-001, to see what affects it has on patients with cancer. TAC-001 is considered investigational in this study because it has not been ...

NCT5812807

Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

This study is currently enrolling.

This study is being done to answer the following question: Among patients with early-stage TNBC who achieve a pCR after preoperative chemotherapy in combination with pembrolizumab, will observation after surgery be as effective ...

NCT06191744

: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

This study is currently enrolling.

The primary objective of the study is to demonstrate that epcoritamab with R2 (ER2) will improve CR30 rates compared to chemoimmunotherapy

NCT06064877

AV-299-23-301: A Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma

This study is currently enrolling.

The main purpose of this study is to investigate the safety, effectiveness, and tolerability (whether side effects can be handled by a participant) of ficlatuzumab at two different doses when given with the established dose of ...

NCTPending

TRIPLE G: A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 versus Placebo on Calorie Intake and Energy Expenditure in Participants with Obesity Under Calorie Restriction

This study is currently enrolling.

Study Purpose: The purposes of this study are to look at the effect of the study drug compared to placebo (a drug that looks like the study drug but has no active medicine) on calorie intake, different uses of energy in the bod ...

NCT05891171

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors

This study is currently enrolling.

Objectives: Primary: Dose Escalation: To identify the recommended doses for expansion (RDEs) of NKT3447 in adult subjects with advanced/metastatic solid tumors Dose Expansion: To evaluate the preliminary antitumor activity of N ...

Subscribe to

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease

A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection

INCLINE-101: A Phase 1/2, open label, dose escalation and expansion study of TAC-001 in patients with select advanced or metastatic solid tumors

Optimice-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy

: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

AV-299-23-301: A Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma

TRIPLE G: A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 versus Placebo on Calorie Intake and Energy Expenditure in Participants with Obesity Under Calorie Restriction

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors

Explore

Institutes